Emerson Electric Co. (EMR). Below are some highlights from the above linked analysis:
Company Description: Emerson Electric Co. designs and supplies product technology, and delivers engineering services and solutions to a wide range of industrial, commercial, and consumer markets around the world.
Fair Value: In calculating fair value, I consider the NPV MMA Differential Fair Value along with these four calculations of fair value, see page 2 of the linked PDF for a detailed description:
1. Avg. High Yield Price
2. 20-Year DCF Price
3. Avg. P/E Price
4. Graham Number
EMR is trading at a discount to only 3.) above. Since EMR's tangible book value is not meaningful, a Graham number can not be calculated. The stock is trading at a 70.6% premium to its calculated fair value of $28.78. EMR did not earn any Stars in this section.
Dividend Analytical Data: In this section there are three possible Stars and three key metrics, see page 2 of the linked PDF for a detailed description:
1. Free Cash Flow Payout
2. Debt To Total Capital
3. Key Metrics
4. Dividend Growth Rate
5. Years of Div. Growth
6. Rolling 4-yr Div. > 15%
EMR earned two Stars in this section for 1.) and 2.) above. A Star was earned since the Free Cash Flow payout ratio was less than 60% and there were no negative Free Cash Flows over the last 10 years. The stock earned a Star as a result of its most recent Debt to Total Capital being less than 45%. The company has paid a cash dividend to shareholders every year since 1947 and has increased its dividend payments for 55 consecutive years.
Dividend Income vs. MMA: Why would you assume the equity risk and invest in a dividend stock if you could earn a better return in a much less risky money market account (MMA) or Treasury bond? This section compares the earning ability of this stock with a high yield MMA. Two items are considered in this section, see page 2 of the linked PDF for a detailed description:
1. NPV MMA Diff.
2. Years to > MMA
The negative NPV MMA Diff. means that on a NPV basis the dividend earnings from an investment in EMR would be less than a similar amount invested in MMA earning a 20-year average rate of 4.1%. If EMR grows its dividend at 2.2% per year, it will never equal a MMA yielding an estimated 20-year average rate of 4.1%.
Memberships and Peers: EMR is a member of the S&P 500, a Dividend Aristocrat and a member of the Broad Dividend Achievers™ Index and a Dividend Champion. The company's peer group includes: Espey Manufacturing & Electronics Corp. (ESP) with a 3.6% yield, Cooper Industries plc (CBE) with a 2.2% yield and Regal Beloit Corporation (RBC) with a 1.2% yield.
Conclusion: EMR did not earn any Stars in the Fair Value section, earned two Stars in the Dividend Analytical Data section and did not earn any Stars in the Dividend Income vs. MMA section for a total of two Stars. This quantitatively ranks EMR as a 2 Star-Weak stock.
Using my D4L-PreScreen.xls model, I determined the share price would need to decrease to $29.33 before EMR's NPV MMA Differential increased to the $500 minimum that I look for in a stock with 55 years of consecutive dividend increases. At that price the stock would yield 4.7%.
Resetting the D4L-PreScreen.xls model and solving for the dividend growth rate needed to generate the target $500 NPV MMA Differential, the calculated rate is 7.5%. This dividend growth rate is well above the 2.2% used in this analysis, thus providing a no margin of safety. EMR has a risk rating of 1.50 which classifies it as a Low risk stock.
EMR has a strong competitive position within its major product categories and a reputation for providing consistent returns to investors. EMR’s advantages include globally branded platforms, new products in the pipeline, a strong balance sheet and free cash flow. The stock is currently trading above my buy price of $28.78. I will wait for its dividend growth rate and dividend fundamentals to improve before adding to my position.
Disclaimer: Material presented here is for informational purposes only. The above quantitative stock analysis, including the Star rating, is mechanically calculated and is based on historical information. The analysis assumes the stock will perform in the future as it has in the past. This is generally never true. Before buying or selling any stock you should do your own research and reach your own conclusion. See my Disclaimer for more information.
Full Disclosure: At the time of this writing, I was long in EMR (0.9% of my Income Portfolio). See a list of all my dividend growth holdings here.
- AT&T Inc. (T) Dividend Stock Analysis
- Lockheed Martin Corp. (LMT) Dividend Stock Analysis
- H.J. Heinz Company (HNZ) Dividend Stock Analysis
- Watsco, Inc. (WSO) Dividend Stock Analysis
- More Stock Analysis
Tags: [EMR] [ESP] [CBE] [RBC]
Popular Posts - Last 7 days
Presented below are my dividend stock and ETF/CEF holdings. This is not a recommendation to buy these securities. I have classified some of...
Monday, October 31, 2011 will mark my fourth full year of writing as Dividends4Life . It is hard to believe another year has passed. Like th...
For many investors, there is no clear conviction as to how they should invest. Today’s investments are guided by what was read yesterday, a...
Like many that came before me, I am on a journey to construct a portfolio that will provide me... Dividends 4 Life
We all want to succeed in everything that we do, including investing in the stock market. Though I have no analytical data to back it up, I ...
Linked here is a detailed quantitative analysis of T. Rowe Price Group Inc. (TROW). Below are some highlights from the above linked analysi...
The Industrials Sector consists of companies that manufacture products or provide business services. The products are often inputs or raw m...
Each Sunday I highlight the Carnivals I participated in over the past week, along with any notable articles that I came across. For those re...
Linked here is a detailed quantitative analysis of Johnson & Johnson (JNJ). Below are some highlights from the above linked analysis: ...
There are income investors and Dividend Growth investors. While the distinction is rather simple, it slips past many casual observers. Inco...